Levi & Korsinsky Launches Class Action Against PepGen Inc. for Investor Recovery

Class Action Lawsuit Against PepGen Inc. (NASDAQ: PEPG)



On July 15, 2025, Levi & Korsinsky LLP announced that it has filed a class action securities lawsuit on behalf of investors in PepGen Inc. This action follows the company's reported allegations of securities fraud that negatively impacted shareholders during the relevant time frame. The class period is defined as occurring between March 7, 2024, and March 3, 2025.

Overview of the Lawsuit



The class action aims to recover losses for those who invested in PepGen Inc. during the specified period. The allegations detail a series of misleading statements made by the company regarding its lead product candidate, PGN-EDO51. The lawsuit notes that the effectiveness and safety of PGN-EDO51 were overstated, leading investors to believe it was more promising than it actually was.

Furthermore, the lawsuit alleges that the second-phase CONNECT2 study undertaken by PepGen was not only dangerous but also deficient in respect to FDA approval requirements. Consequently, the company faced the likelihood of halting the CONNECT2 study, which could drastically impact PGN-EDO51’s clinical and commercial prospects.

Key Allegations



The critical allegations for this case revolve around the following points:
1. Misleading Statements: It is asserted that PepGen's leadership made false statements about the potential of PGN-EDO51, leading investors to believe in the product’s viability and safety.
2. Deficient CONNECT2 Study: Questions arise about the safety of the CONNECT2 study, which reportedly failed to meet necessary standards for FDA approval.
3. Falsely Assured Public Statements: The complaint indicates that the company’s public communications regarding PGN-EDO51’s prospects were grossly misleading at all times relevant to the lawsuit.

Investor Actions



Investors who believe they have incurred losses during the stated period are encouraged to participate in the lawsuit. They have until August 8, 2025, to submit requests for the court to appoint them as lead plaintiffs. Notably, becoming a lead plaintiff is not a condition for potential recovery.

The firm assures class members that they may be entitled to compensation without needing to bear any upfront costs or fees. This presents a fair opportunity for affected shareholders to recover their losses without financial risk.

Why Choose Levi & Korsinsky?



Levi & Korsinsky has earned a strong reputation over the last two decades, having recovered hundreds of millions of dollars for aggrieved investors. The firm specializes in complex securities litigation with a dedicated team of over 70 professionals ready to advocate for their clients. They have consistently ranked among the top firms in the field according to the ISS Securities Class Action Services, highlighting their expertise and success rate in high-stakes cases.

Contact Information



For investors wishing to join the class action or seeking more information, contacting Levi & Korsinsky directly is recommended.
  • - Email: info@zlk.com
  • - Phone: (212) 363-7500
  • - Address: 33 Whitehall Street, 17th Floor, New York, NY 10004

In conclusion, the current lawsuit against PepGen Inc. underscores the importance of transparency within the biotech sector and highlights the steps investors can take to protect their interests. As the case continues to evolve, it will be critical to monitor developments closely for all stakeholders involved.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.